# INSMED Inc (INSM)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/insmed-inc/ JSON: https://steadybase.io/company/insmed-inc.json Checked Nov 10, 2026. Latest filing read: Oct 29, 2026.

## Company

- Legal name: INSMED Inc
- Ticker: INSM (Nasdaq)
- SEC CIK: 0001104506
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Bridgewater, NJ
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: insmed.com
- LinkedIn: https://www.linkedin.com/company/insmed
- Next earnings date: Feb 4, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $606.4M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 19, 2026). Source: https://www.sec.gov/Archives/edgar/data/1104506/000110450626000009/0001104506-26-000009-index.html
- Operating income: -$1.2B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 19, 2026). Source: https://www.sec.gov/Archives/edgar/data/1104506/000110450626000009/0001104506-26-000009-index.html
- Net income: -$1.3B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 19, 2026). Source: https://www.sec.gov/Archives/edgar/data/1104506/000110450626000009/0001104506-26-000009-index.html
- SG&A: $701.2M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 19, 2026). Source: https://www.sec.gov/Archives/edgar/data/1104506/000110450626000009/0001104506-26-000009-index.html
- Employees: 1,664 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1104506/000110450626000009/insm-20251231.htm
- Shares outstanding: 219,380,309 as of Oct 23, 2026 (10-Q filed Oct 29, 2026). Source: https://www.sec.gov/Archives/edgar/data/1104506/000110450626000047/0001104506-26-000047-index.html
- Auditor: Ernst & Young LLP, Iselin, New Jersey, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1104506/000110450626000009/insm-20251231.htm

## Business

We are a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Our commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. To complement our internal research and development, we also actively evaluate in-licensing and acquisition opportunities for commercial products, product candidates and technologies.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1104506/000110450626000009/insm-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $606.4M | -$1.2B | -$1.3B | $701.2M |
| Dec 31, 2024 | $363.7M | -$878.3M | -$913.8M | $461.1M |
| Dec 31, 2023 | $305.2M | -$709.6M | -$749.6M | $344.5M |
| Dec 31, 2022 | $245.4M | -$457.3M | -$481.5M | $265.8M |
| Dec 31, 2021 | $188.5M | -$375.1M | -$434.7M | $234.3M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/insmed-inc.json

## Officers and directors

- Will Lewis, Chair and Chief Executive Officer of Insmed. LinkedIn: https://linkedin.com/in/will-lewis-aa89161a8. Source: 8-K filed Oct 29, 2026, https://www.sec.gov/Archives/edgar/data/1104506/000114036126041097/ef20084500_ex99-1.htm
- William Lewis, Chair and CEO. Source: Form 4 filed Jul 24, 2026, https://www.sec.gov/Archives/edgar/data/1104506/000140205126000042/0001402051-26-000042-index.htm
- Sara Bonstein, Chief Financial Officer. LinkedIn: https://linkedin.com/in/sara-bonstein-92b4a220. Source: Form 4 filed Jun 5, 2026, https://www.sec.gov/Archives/edgar/data/1104506/000160401926000010/0001604019-26-000010-index.htm
- Roger Adsett, Chief Operating Officer. Source: Form 4 filed Aug 12, 2026, https://www.sec.gov/Archives/edgar/data/1104506/000168590426000014/0001685904-26-000014-index.htm
- Patrick Kevin Kane, Corporate Controller. Source: Form 3 filed Nov 3, 2026, https://www.sec.gov/Archives/edgar/data/1104506/000216217726000003/0002162177-26-000003-index.htm
- Martina Flammer M.D., Chief Medical Officer. LinkedIn: https://linkedin.com/in/martina-flammer-md-mba-1b2b288. Source: Form 4 filed Aug 7, 2026, https://www.sec.gov/Archives/edgar/data/1104506/000179696026000020/0001796960-26-000020-index.htm
- Michael Alexander Smith, Chief Legal Officer. Source: Form 4 filed Jun 24, 2026, https://www.sec.gov/Archives/edgar/data/1104506/000187027826000020/0001870278-26-000020-index.htm
- Michael Smith, Chief Legal Officer. Source: 10-K filed Feb 19, 2026, https://www.sec.gov/Archives/edgar/data/1104506/000110450626000009/insm-20251231.htm
- S. Nicole Schaeffer, Chief People Strategy Officer. Source: 10-K filed Feb 19, 2026, https://www.sec.gov/Archives/edgar/data/1104506/000110450626000009/insm-20251231.htm
- Orlov S. Nicole Schaeffer, Chief People Strategy Officer. Source: Form 4 filed Jan 6, 2026, https://www.sec.gov/Archives/edgar/data/1104506/000140101726000002/0001401017-26-000002-index.htm
- Samuele Butera, SVP, GM, Global Respiratory. LinkedIn: https://linkedin.com/in/samuelebutera. Source: Form 4 filed Jun 24, 2026, https://www.sec.gov/Archives/edgar/data/1104506/000214009826000005/0002140098-26-000005-index.htm
- Elizabeth McKee Anderson, Director. Source: 10-K filed Feb 19, 2026, https://www.sec.gov/Archives/edgar/data/1104506/000110450626000009/insm-20251231.htm

## Recent 8-K events

- Oct 29, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1104506/000114036126041097/ef20084500_8k.htm
- Oct 20, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1104506/000114036126040177/ef20084030_8k.htm
- Oct 5, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1104506/000114036126038529/ef20083216_8k.htm
- Aug 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_8k.htm
- Jul 16, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1104506/000114036126028602/ef20078093_8k.htm
- May 15, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1104506/000114036126021648/ef20073378_8k.htm
- May 7, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1104506/000114036126019430/ef20072589_8k.htm
- Apr 7, 2026: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1104506/000114036126013659/ef20070042_8k.htm
- Mar 23, 2026: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1104506/000114036126010651/ef20068516_8k.htm
- Feb 19, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1104506/000114036126006116/ef20066055_8k.htm

## Insider trades (Form 4)

- Sep 9, 2026: David R. Brennan (Director) sold 25,000 shares, about $3.1M. Source: https://www.sec.gov/Archives/edgar/data/1104506/000160930526000009/0001609305-26-000009-index.htm
- Aug 17, 2026: Melvin Sharoky Md (Director) sold 5,000 shares, about $637,650. Source: https://www.sec.gov/Archives/edgar/data/1104506/000118263326000010/0001182633-26-000010-index.htm
- Aug 10, 2026: Roger Adsett (Chief Operating Officer) sold 239,850 shares, about $32.0M. Source: https://www.sec.gov/Archives/edgar/data/1104506/000168590426000014/0001685904-26-000014-index.htm
- Aug 6, 2026: Martina Flammer M.D. (Chief Medical Officer) sold 27,173 shares, about $3.5M. Source: https://www.sec.gov/Archives/edgar/data/1104506/000179696026000020/0001796960-26-000020-index.htm
- Jul 23, 2026: William Lewis (Chair and CEO) sold 10,700 shares, about $1.1M. Source: https://www.sec.gov/Archives/edgar/data/1104506/000140205126000042/0001402051-26-000042-index.htm
- Jul 9, 2026: William Lewis (Chair and CEO) sold 10,699 shares, about $1.3M. Source: https://www.sec.gov/Archives/edgar/data/1104506/000140205126000040/0001402051-26-000040-index.htm
- Jul 6, 2026: Martina Flammer M.D. (Chief Medical Officer) sold 12,302 shares, about $1.4M. Source: https://www.sec.gov/Archives/edgar/data/1104506/000179696026000018/0001796960-26-000018-index.htm
- Jun 25, 2026: William Lewis (Chair and CEO) sold 21,398 shares, about $2.2M. Source: https://www.sec.gov/Archives/edgar/data/1104506/000140205126000038/0001402051-26-000038-index.htm
- Jun 22, 2026: Michael Alexander Smith (Chief Legal Officer) sold 1,806 shares, about $173,051. Source: https://www.sec.gov/Archives/edgar/data/1104506/000187027826000020/0001870278-26-000020-index.htm
- Jun 8, 2026: William Lewis (Chair and CEO) sold 6,515 shares, about $612,605. Source: https://www.sec.gov/Archives/edgar/data/1104506/000140205126000035/0001402051-26-000035-index.htm
- Jun 5, 2026: Martina Flammer M.D. (Chief Medical Officer) sold 4,424 shares, about $455,248. Source: https://www.sec.gov/Archives/edgar/data/1104506/000179696026000016/0001796960-26-000016-index.htm
- Jun 3, 2026: Michael Alexander Smith (Chief Legal Officer) sold 2,159 shares, about $220,801. Source: https://www.sec.gov/Archives/edgar/data/1104506/000187027826000017/0001870278-26-000017-index.htm
- Jun 3, 2026: Roger Adsett (Chief Operating Officer) sold 2,370 shares, about $242,380. Source: https://www.sec.gov/Archives/edgar/data/1104506/000168590426000012/0001685904-26-000012-index.htm
- Jun 3, 2026: Sara Bonstein (Chief Financial Officer) sold 2,404 shares, about $245,857. Source: https://www.sec.gov/Archives/edgar/data/1104506/000160401926000010/0001604019-26-000010-index.htm
- Jun 3, 2026: William Lewis (Chair and CEO) sold 7,605 shares, about $777,763. Source: https://www.sec.gov/Archives/edgar/data/1104506/000140205126000032/0001402051-26-000032-index.htm

## What management said

- "The third quarter marked another period of meaningful progress, defined by commercial momentum, regulatory achievements, and advancement across our diversified pipeline" Will Lewis, Chair and Chief Executive Officer of Insmed (8-K filed Oct 29, 2026). Source: https://www.sec.gov/Archives/edgar/data/1104506/000114036126041097/ef20084500_ex99-1.htm

## Latest filings

- 8-K filed Oct 29, 2026: https://www.sec.gov/Archives/edgar/data/1104506/000114036126041097/ef20084500_8k.htm
- 10-K filed Feb 19, 2026: https://www.sec.gov/Archives/edgar/data/1104506/000110450626000009/insm-20251231.htm
- 10-Q filed Oct 29, 2026: https://www.sec.gov/Archives/edgar/data/1104506/000110450626000047/insm-20260930.htm
- DEF 14A filed Apr 1, 2026: https://www.sec.gov/Archives/edgar/data/1104506/000110450626000022/insm-20260401.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/